Page 164 - Orange Book Cumulative Supplement 10 October 2012

A - 27
PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012
See List footnote for information regarding List content

PATENT PATENT EXCLUSIVITY
EXPIRATION PATENT DELIST EXCLUSIVITY EXPIRATION
APPL/PROD DATE REQUESTED DATE
NO PATENT NO CODES CODE(S)
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO
N201281 002 6303661 Apr 24, 2017 U-802 NCE May 02, 2016
6890898 Feb 02, 2019 U-1039 NC Jan 30, 2015
7078381 Feb 02, 2019 U-1039
7407955 Aug 12, 2023 DS DP
7459428 Feb 02, 2019 U-1039
8119648 Aug 12, 2023 U-802
8178541 Aug 12, 2023 DP U-775
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO
N201281 003 6303661 Apr 24, 2017 U-802 NCE May 02, 2016
6890898 Feb 02, 2019 U-1039 NC Jan 30, 2015
7078381 Feb 02, 2019 U-1039
7407955 Aug 12, 2023 DS DP
7459428 Feb 02, 2019 U-1039
8119648 Aug 12, 2023 U-802
8178541 Aug 12, 2023 DP U-775
LIRAGLUTIDE RECOMBINANT - VICTOZA
N022341 001 8114833 Aug 13, 2025 DP M-115 Apr 06, 2015
LISDEXAMFETAMINE DIMESYLATE - VYVANSE
N021977 001 7662788 Feb 24, 2023 U-727 I-645 Jan 31, 2015
7713936 Feb 24, 2023 U-727
LISDEXAMFETAMINE DIMESYLATE - VYVANSE
N021977 002 7662788 Feb 24, 2023 U-727 I-645 Jan 31, 2015
7713936 Feb 24, 2023 U-727

LISDEXAMFETAMINE DIMESYLATE - VYVANSE
N021977 003 7662788 Feb 24, 2023 U-727 I-645 Jan 31, 2015
7713936 Feb 24, 2023 U-727

LISDEXAMFETAMINE DIMESYLATE - VYVANSE
N021977 004 7662788 Feb 24, 2023 U-727 I-645 Jan 31, 2015
7671030 Feb 24, 2023 DP U-727
7674774 Mar 18, 2023 DP U-842
7678771 Mar 25, 2023 DP U-842
7687467 Apr 08, 2023 DP U-842
7713936 Feb 24, 2023 U-727
7718619 Feb 24, 2023 DP U-842
7723305 Feb 24, 2023 DP U-842
LISDEXAMFETAMINE DIMESYLATE - VYVANSE
N021977 005 7662788 Feb 24, 2023 U-727 I-645 Jan 31, 2015
7713936 Feb 24, 2023 U-727
LISDEXAMFETAMINE DIMESYLATE - VYVANSE
N021977 006 7662788 Feb 24, 2023 U-727 I-645 Jan 31, 2015
7713936 Feb 24, 2023 U-727

LOPINAVIR; RITONAVIR - KALETRA
N021906 001 8268349 Aug 25, 2024 DP
8268349*PED Feb 25, 2025